Literature DB >> 4292958

The margin of safety of neuromuscular transmission.

W D Paton, D R Waud.   

Abstract

1. The margin of safety for neuromuscular transmission in the tibialis and sartorius muscles of the cat has been determined by measuring the ratio by which end-plate depolarization produced by succinylcholine, decamethonium, octamethonium or iodocholine is antagonized, in the presence of neuromuscular block produced by tubocurarine, gallamine or DF-596. The estimate of the margin of safety was independent of the particular drugs chosen for the measurement.2. To produce threshold block to indirect stimulation once every 10 sec, a fractional occupancy by the antagonist of 0.76 +/- 0.05 (S.D.) was required; for nearly complete block, an occupancy of 0.917 +/- 0.16 (S.D.) was required. These figures correspond to factors of safety of 4.1 and 12 for the most sensitive and the most resistant groups of fibres respectively.3. The interaction between the agonists and the antagonists, when tested over a wide range of dosage, did not conform with the conditions of full competitive equilibrium. It was concluded that this arose, not because of some interfering non-competitive process, but because, during the relatively brief exposure to agonist, the equilibrium between the antagonist and the receptors is not significantly disturbed. An analysis of this condition of quasi-equilibrium is given. A correction downwards of the direct estimates of the margin of safety is required, but this proves to be small, about 8%, and may not be significant.4. The safety factor diminished when the motor nerve had been cut more than 5 hr; it is suggested that this represents an early sign of nerve degeneration.5. With dog sartorius muscle, results similar to those in the cat were obtained. But for deep block in the rabbit, the safety factor was only about 4.6. The existence of a substantial margin of safety influences considerably the interpretation of the time course of action of blocking drugs, and of comparisons between responses to nervous excitation and drug injection.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4292958      PMCID: PMC1365439          DOI: 10.1113/jphysiol.1967.sp008237

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  23 in total

1.  Quantitative studies of antagonists for 5-hydroxytryptamine.

Authors:  J H GADDUM; K A HAMEED; D E HATHWAY; F F STEPHENS
Journal:  Q J Exp Physiol Cogn Med Sci       Date:  1955-01

2.  Submaxillary and sublingual secretion in cats during degeneration of post-ganglionic parasympathetic fibres.

Authors:  N EMMELIN
Journal:  J Physiol       Date:  1962-07       Impact factor: 5.182

3.  A study of curare action with an electrical micromethod.

Authors:  L DEL CASTILLO; B KATZ
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-05-07

4.  Affinity, intrinsic activity and drug interactions.

Authors:  E J ARIENS; J M VAN ROSSUM; A M SIMONIS
Journal:  Pharmacol Rev       Date:  1957-06       Impact factor: 25.468

5.  A study of the desensitization produced by acetylcholine at the motor end-plate.

Authors:  B KATZ; S THESLEFF
Journal:  J Physiol       Date:  1957-08-29       Impact factor: 5.182

6.  Acetylcholine content of the rabbit plantaris muscle after denervation.

Authors:  C O Hebb
Journal:  J Physiol       Date:  1962-09       Impact factor: 5.182

7.  The analysis of the mode of action of curare on neuromuscular transmission; the effect of temperature changes.

Authors:  P E B HOLMES; D J JENDEN; D B TAYLOR
Journal:  J Pharmacol Exp Ther       Date:  1951-12       Impact factor: 4.030

8.  The kinetics of action of acetylcholine antagonists in smooth muscle.

Authors:  H P Rang
Journal:  Proc R Soc Lond B Biol Sci       Date:  1966-04-19

9.  An alkylating derivative of benzilylcholine with specific and long-lasting parasympatholytic activity.

Authors:  E W Gill; H P Rang
Journal:  Mol Pharmacol       Date:  1966-07       Impact factor: 4.436

10.  THE GANGLION BLOCKING ACTION OF PROCAINAMIDE.

Authors:  W D PATON; J W THOMPSON
Journal:  Br J Pharmacol Chemother       Date:  1964-02
View more
  71 in total

1.  What anesthesiologist should know about neuromuscular monitoring today?

Authors:  N Ueda; T Muteki; H Tsuda
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

2.  Monte Carlo simulation of buffered diffusion into and out of a model synapse.

Authors:  James P Dilger
Journal:  Biophys J       Date:  2010-03-17       Impact factor: 4.033

3.  A regional technique for the study of sensitivity to curare in human muscle.

Authors:  J C Brown; J E Charlton; D J White
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-01       Impact factor: 10.154

4.  Modeling of twitch fade based on slow interaction of nondepolarizing muscle relaxants with the presynaptic receptors.

Authors:  Shashi B Bhatt; Anton Amann; Vladimir Nigrovic
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-03       Impact factor: 2.745

5.  Regional curare for the reduction of the safety factor in human motor end-plates studied with single fibre electromyography.

Authors:  H H Schiller; E Stålberg; M S Schwartz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-08       Impact factor: 10.154

6.  The pharmacological characterization of 5-HT3 receptors in three isolated preparations derived from guinea-pig tissues.

Authors:  A Butler; C J Elswood; J Burridge; S J Ireland; K T Bunce; G J Kilpatrick; M B Tyers
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

7.  Interaction of competitive antagonists: the anti-curare action of hexamethonium and other antagonists at the skeletal neuromuscular junction.

Authors:  J G Blackman; R W Gauldie; R J Milne
Journal:  Br J Pharmacol       Date:  1975-05       Impact factor: 8.739

8.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 9.  [Sugammadex. New pharmacological concept for antagonizing rocuronium and vecuronium].

Authors:  H J Sparr; L H Booij; T Fuchs-Buder
Journal:  Anaesthesist       Date:  2009-01       Impact factor: 1.041

10.  Actions of bretylium tosylate at the neuromuscular junction.

Authors:  C B Ferry; B Norris
Journal:  Br J Pharmacol       Date:  1971-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.